FindTrial
Sign In

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

A Local, Multicentre, Open Label Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00992654
Enrollment
Unknown
Registered
2009-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2018-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus (HIV)

Keywords

Open Label Access Program, Treatment experienced

Brief summary

The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.

Interventions

DRUGOpen Label Treatment Access: Maraviroc

Oral dosing twice daily. The dose will depend on the optimized background therapy.

Sponsors

Pfizer
CollaboratorINDUSTRY
ViiV Healthcare
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc. * Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures.

Exclusion criteria

* Subjects who discontinued in A4001050 study. * Unable to provide consent.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026